Miglitol (72432-03-2) is an α-glucosidase inhibitor which induces an enhanced and prolonged release of glucagon-like peptide-1, regulating appetite and stabilizing body weight in humans1. Miglitol displays anti-atherothrombotic effect by reducing platelet activation2 and raising circulating adiponectin levels3 in patients with type 2 diabetes. Clinically useful antidiabetic agent.
1) Lee et al. (2002), The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics; Diabetes Obes. Metab., 4 329
2) Nomura et al. (2011), Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus; Int. J. Gen. Med., 4 539
3) Yokoyama et al. (2007), Miglitol increases the adiponectin level and decreases urinary ambumin excretion in patients with type 2 diabetes mellitus; Metabolism, 56 1458